000 01228 a2200301 4500
005 20250516153609.0
264 0 _c20140204
008 201402s 0 0 eng d
022 _a1873-7560
024 7 _a10.1016/j.eururo.2013.04.027
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aInman, Brant A
245 0 0 _aWords of wisdom. Re: final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.
_h[electronic resource]
260 _bEuropean urology
_cJul 2013
300 _a171-2 p.
_bdigital
500 _aPublication Type: Journal Article; Comment
650 0 4 _aCarcinoma, Transitional Cell
_xsurgery
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aKidney Neoplasms
_xsurgery
650 0 4 _aMale
650 0 4 _aNephrectomy
_xmethods
650 0 4 _aUreter
_xsurgery
650 0 4 _aUreteral Neoplasms
_xsurgery
650 0 4 _aUreteroscopy
_xmethods
773 0 _tEuropean urology
_gvol. 64
_gno. 1
_gp. 171-2
856 4 0 _uhttps://doi.org/10.1016/j.eururo.2013.04.027
_zAvailable from publisher's website
999 _c22817382
_d22817382